Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial (Q44493061)

3 December 2017

Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial (English)

1 reference

3 December 2017

0 references

Helen Athanassiou

1

1 reference

3 December 2017

Dosia Antonadou

2

1 reference

3 December 2017

Nikos Coliarakis

3

1 reference

3 December 2017

Athina Kouveli

4

1 reference

3 December 2017

Maria Synodinou

5

1 reference

3 December 2017

Michalakis Paraskevaidis

6

1 reference

3 December 2017

George Sarris

7

1 reference

3 December 2017

Gregory R Georgakopoulos

8

1 reference

3 December 2017

Katerina Panousaki

9

1 reference

3 December 2017

Pantelis Karageorgis

10

1 reference

3 December 2017

Nicolas Throuvalas

11

1 reference

3 December 2017

Oncology Hellenic Group

12

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

International Journal of Radiation Oncology Biology Physics

3 December 2017

1 reference

3 December 2017

56

1 reference

3 December 2017

4

1 reference

3 December 2017

1154-1160

1 reference

The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma.

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Late complications after postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases with application of linear-quadratic model.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Chemical modifiers of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Use of radiation with or without WR-2721 in advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

The incidence and clinical consequences of treatment-related bowel injury

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Postoperative radiation therapy of rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Mechanism of Action of Aminothiol Radioprotectors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Alterations in oxygen transport following WR-2721

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900187-1

7 January 2021

10.1016/S0360-3016(03)00187-1

Identifiers

DOI

1 reference

3 December 2017

1 reference